Corcept Therapeutics
CORT
$96.66
+6.36%
Corcept Therapeutics is a commercial-stage pharmaceutical company focused on developing and marketing medications that modulate the cortisol hormone to treat severe metabolic, oncologic, and neuropsychiatric disorders, with its marketed product Korlym (mifepristone) for Cushing's syndrome. The company holds a unique position as the only provider of a FDA-approved treatment for hypercortisolism, giving it a niche but defensible market leadership. Investor attention is currently centered on the recent FDA approval of its new cancer drug Lifyorli, which expands its pipeline beyond Cushing's and has driven a significant re-rating of the stock, alongside ongoing clinical trials for relacorilant and other candidates that could address larger markets.…
CORT
Corcept Therapeutics
$96.66
Related headlines
Investment Opinion: Should I buy CORT Today?
Rating: Buy. Corcept offers a unique opportunity as a commercial-stage biotech with a newly approved oncology drug (Lifyorli) that can drive a step-change in growth, supported by a debt-free balance sheet and high gross margins. The consensus analyst rating is Buy with an average target of $97.50, implying 7.7% upside.
Supporting evidence includes: (1) trailing P/E of 36.6x, below its 5-year average of ~40x, suggesting reasonable valuation; (2) revenue growth of 4.9% YoY, with potential acceleration from Lifyorli; (3) gross margin of 98.3%, far above industry average; (4) free cash flow of $119.8 million TTM, providing financial flexibility. The forward P/E of 28.2x implies expected earnings growth of ~30%, which is achievable if Lifyorli ramps.
Key risks include: (1) slower-than-expected Lifyorli adoption; (2) continued operating expense inflation; (3) competitive pressure in Cushing's. This Buy would downgrade to Hold if revenue growth falls below 5% or if the stock exceeds $110 without earnings confirmation. Overall, Corcept appears fairly valued relative to its growth prospects and premium margins, with upside potential from pipeline catalysts.
Sign up to view all
CORT 12-Month Price Forecast
Corcept's outlook is bullish over the next 12 months, driven by the recent FDA approval of Lifyorli and a strong balance sheet. The base case of 50% probability assumes moderate growth and stable margins, aligning with the average analyst target. The bull case (30%) offers significant upside if Lifyorli exceeds expectations, while the bear case (20%) reflects execution risks. The stance would upgrade to high confidence if Q2 2026 revenue shows acceleration above 15% YoY, and downgrade to neutral if Lifyorli sales disappoint or operating losses widen.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Corcept Therapeutics's 12-month outlook, with a consensus price target around $106.00 and implied upside of +9.7% versus the current price.
Average Target
$106.00
0 analysts
Implied Upside
+9.7%
vs. current price
Analyst Count
—
covering this stock
Price Range
$88 - $135
Analyst target range
Corcept is covered by 4 analysts, with a consensus recommendation of 'Buy' (mean rating of 1.75 on a 1-5 scale, where 1 is Strong Buy). The average price target is $97.50, implying 7.7% upside from the current price of $90.52. The distribution is bullish: 3 Buy ratings and 1 Hold (Peer Perform), with no Sell ratings. Recent upgrades include UBS moving from Neutral to Buy on May 13, 2026, and Wolfe Research upgrading from Underperform to Peer Perform on March 26, 2026, reflecting growing optimism.
The target range spans from a low of $72.00 to a high of $135.00, a wide spread of 87.5% from low to high, indicating high uncertainty about the stock's future. The high target of $135 assumes successful commercialization of Lifyorli and potential upside from pipeline candidates like relacorilant, implying a 49% upside from current levels. The low target of $72.00 prices in risks such as slower-than-expected Lifyorli adoption, competitive pressure, or clinical trial setbacks, representing a 20% downside. The wide range suggests that while the consensus is bullish, there is significant divergence in expectations, typical for a biotech with a binary pipeline event. The recent insider sale (pre-scheduled) does not appear to have dampened analyst sentiment, as ratings have remained positive.
Bulls vs Bears: CORT Investment Factors
Corcept presents a compelling bull case driven by its recent FDA approval of Lifyorli, a pristine balance sheet, and high gross margins, which support a premium valuation. However, the Q1 net loss, decelerating revenue growth, and elevated short interest introduce significant risks. The bull case currently has stronger evidence given the transformative potential of Lifyorli and strong analyst support, but the key tension is whether the company can translate pipeline expansion into sustained earnings growth. If Lifyorli ramps successfully, the stock could re-rate higher; if not, the premium valuation leaves little room for error.
Bullish
- FDA Approval of Lifyorli Expands Pipeline: The March 2026 FDA approval of Lifyorli, a new cancer drug, provides a second commercial product and diversifies revenue beyond the Cushing's franchise. This catalyst drove a 96.1% surge in the stock over three months, signaling strong market optimism.
- Strong Balance Sheet with Zero Debt: Corcept has a debt-to-equity ratio of 0.0094 and a current ratio of 2.92, indicating ample liquidity and financial flexibility. The company generated $119.8 million in free cash flow over the trailing twelve months, supporting R&D investment without dilution.
- High Gross Margins Provide Pricing Power: Gross margin stands at 98.3%, far above the pharmaceutical industry average of ~60%. This reflects the high profitability of its branded product Korlym and the potential for strong margins on new drugs like Lifyorli.
- Analyst Consensus Buy with Upside Potential: The average analyst price target is $97.50, implying 7.7% upside from the current price of $90.52. The high target of $135 suggests 49% upside if pipeline and commercial execution succeed, with 3 Buy and 1 Hold ratings.
Bearish
- Q1 2026 Net Loss Raises Profitability Concerns: The company posted a net loss of -$31.2 million in Q1 2026, compared to net income of $24.3 million in Q4 2025. Operating expenses surged, with SG&A rising to $145.4 million from $90.7 million a year ago, pressuring margins.
- Revenue Growth Decelerating: Q1 2026 revenue grew only 4.9% YoY to $164.9 million, down from 11.1% YoY growth in Q2 2025. The sequential decline from Q4 2025's $202.1 million suggests seasonal weakness and potential market saturation for Korlym.
- Elevated Valuation Premium to Peers: The trailing P/E of 36.6x is 66% above the pharmaceutical industry average of 22x. While justified by high margins and growth, any earnings miss could trigger multiple compression, especially if Lifyorli sales disappoint.
- High Short Ratio Signals Bearish Sentiment: The short ratio of 8.57 days is elevated, indicating significant bearish bets. This could reflect skepticism about the sustainability of the recent rally or concerns about pipeline execution risks.
CORT Technical Analysis
Corcept is in a powerful sustained uptrend, with the stock up 23.8% over the past year and currently trading at 95.2% of its 52-week range ($28.66 to $95.11). The price sits near the highs, reflecting strong momentum and bullish sentiment, though it also raises the risk of overextension. The 52-week low of $28.66 provides a clear support level, while the high of $95.11 acts as resistance; a breakout above $95.11 would signal further upside, while a drop below $28.66 would indicate a trend reversal. Beta is 0.46, meaning the stock is significantly less volatile than the market, which is unusual for a biotech and suggests the stock may have more room to run if sector volatility increases.
Short-term momentum is exceptionally strong, with the stock gaining 10.7% in the past month and an astonishing 96.1% over the past three months. This acceleration far outpaces the longer-term 1-year gain, indicating a recent catalyst-driven surge—likely the FDA approval of Lifyorli in March 2026. The 1-month relative strength of 10.4% versus the S&P 500's 0.3% confirms the stock is in a powerful momentum phase. However, such rapid gains can lead to mean reversion, and the stock pulled back from $94.04 on July 7 to $90.52 by July 17, suggesting some profit-taking.
Key support lies at the 52-week low of $28.66, though the stock is far above that level; more immediate support may be found near $85 (the July 13 low). Resistance is at the 52-week high of $95.11, and a breakout above that level could target the analyst high of $135. The stock's low beta of 0.46 implies it is less sensitive to broad market moves, which may appeal to risk-averse investors but also means that a market downturn could still weigh on the stock. The short ratio of 8.57 days is elevated, indicating significant bearish bets that could fuel a short squeeze if positive news continues.
Beta
0.46
0.46x market volatility
Max Drawdown
-64.4%
Largest decline past year
52-Week Range
$29-$97
Price range past year
Annual Return
+41.3%
Cumulative gain past year
| Period | CORT Return | S&P 500 |
|---|---|---|
| 1m | +21.1% | +0.6% |
| 3m | +109.9% | +3.4% |
| 6m | +119.8% | +7.1% |
| 1y | +41.3% | +16.4% |
| ytd | +153.0% | +8.3% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
CORT Fundamental Analysis
Revenue has been growing steadily, with the most recent quarter (Q1 2026) reporting $164.9 million, up 4.9% year-over-year from $157.2 million in Q1 2025. However, the growth rate has decelerated from the 11.1% YoY growth seen in Q2 2025 ($194.4 million vs. $163.8 million in Q2 2024). The sequential decline from Q4 2025's $202.1 million is typical for seasonal patterns, but the overall trajectory remains positive, driven by Korlym sales and the recent launch of Lifyorli. The company's revenue is highly concentrated in its Cushing's franchise, which is a niche market, but the pipeline expansion into oncology could drive a step-change in growth.
Profitability has been inconsistent: the company posted a net loss of -$31.2 million in Q1 2026, compared to net income of $24.3 million in Q4 2025 and $35.1 million in Q2 2025. The loss was driven by a sharp increase in operating expenses, particularly R&D ($66.3 million in Q1 2026 vs. $60.7 million in Q1 2025) and SG&A ($145.4 million vs. $90.7 million). Gross margin remains exceptionally high at 98.3%, typical for a specialty pharmaceutical company with a branded product. The negative net margin of -18.9% in Q1 2026 is a concern, but the company has been profitable on a trailing twelve-month basis (net income of $119.8 million in free cash flow).
The balance sheet is very strong with zero debt and a debt-to-equity ratio of just 0.0094. The current ratio of 2.92 indicates ample liquidity, and the company generated $119.8 million in free cash flow over the trailing twelve months, despite the Q1 loss. ROE is 15.4%, reflecting solid returns on equity. The company has no dividend, which is typical for a growth-stage biotech. The strong cash position and lack of debt provide financial flexibility to fund R&D and potential acquisitions without diluting shareholders.
Quarterly Revenue
$164903000.0B
2026-03
Revenue YoY Growth
+4.9%
YoY Comparison
Gross Margin
98.3%
Latest Quarter
Free Cash Flow
$119788000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Open an Account, get $2 TSLA now!
Valuation Analysis: Is CORT Overvalued?
Since net income is positive on a trailing twelve-month basis (TTM net income of approximately $119.8 million), the most appropriate valuation metric is the P/E ratio. The trailing P/E is 36.6x, while the forward P/E is 28.2x, implying that the market expects earnings to grow by about 30% over the next year. The gap between trailing and forward P/E suggests the market is pricing in the recent FDA approval and pipeline progress, which should boost future earnings.
Compared to the pharmaceutical industry average P/E of around 22x, Corcept trades at a 66% premium. This premium is justified by the company's high gross margins (98.3% vs. industry average of ~60%), strong revenue growth (4.9% YoY in the latest quarter), and the potential for a new growth driver from Lifyorli. However, the premium also reflects the risk of pipeline dependence and the niche nature of its current market.
Historically, Corcept's trailing P/E has ranged from 17.7x (Q4 2021) to 150.3x (Q1 2025), with the current 36.6x near the lower end of its recent range. The stock's P/E has compressed from the 150x level seen in early 2025 as earnings have grown, indicating that the valuation is becoming more reasonable. The current P/E is below the 5-year average of approximately 40x, suggesting the stock may still have room to run if earnings continue to grow.
PE
36.6x
Latest Quarter
vs. Historical
Mid-Range
5-Year PE Range 18x~56x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
51.2x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: Corcept's Q1 2026 net loss of -$31.2 million, driven by a sharp increase in SG&A expenses to $145.4 million (up 60% YoY), highlights margin pressure. The company's revenue growth decelerated to 4.9% YoY, and its reliance on a single product (Korlym) for the bulk of sales creates concentration risk. While the balance sheet is strong with zero debt, the negative net margin of -18.9% in Q1 is a concern if operating expenses continue to outpace revenue growth.
Market & Competitive Risks: The stock trades at a trailing P/E of 36.6x, a 66% premium to the pharmaceutical industry average of 22x, making it vulnerable to valuation compression if growth disappoints. The elevated short ratio of 8.57 days indicates significant bearish sentiment, and the low beta of 0.46 may limit upside in a broad market rally. Competitive threats include potential new entrants in Cushing's treatment and the risk that Lifyorli fails to gain market share in oncology.
Worst-Case Scenario: If Lifyorli commercial launch underperforms, operating expenses remain elevated, and revenue growth stalls, the stock could fall to the analyst low target of $72.00, representing a 20% decline from the current price of $90.52. In a more severe scenario, a return to the 52-week low of $28.66 would imply a 68% loss, though this is unlikely given the company's cash position and pipeline progress.
FAQ
The key risks are: (1) Financial: Q1 2026 net loss of -$31.2 million and rising SG&A expenses (up 60% YoY) could pressure profitability if revenue growth doesn't accelerate. (2) Competitive: Dependence on the niche Cushing's market for Korlym makes it vulnerable to new entrants. (3) Pipeline: Lifyorli commercial launch may underperform, and clinical trials for relacorilant could fail. (4) Valuation: The premium P/E of 36.6x leaves little room for error; any earnings miss could trigger multiple compression. The most severe risk is a 20% decline to the analyst low target of $72.
The 12-month forecast is bullish with a base case (50% probability) targeting $85-$110, aligned with the average analyst target of $97.50. The bull case (30% probability) targets $110-$135, driven by strong Lifyorli adoption, while the bear case (20% probability) targets $72-$85 if execution falters. The most likely scenario is moderate growth, with the stock trading near current levels or slightly higher. Key assumptions include Lifyorli contributing to revenue acceleration and operating expenses stabilizing.
Corcept's trailing P/E of 36.6x is 66% above the pharmaceutical industry average of 22x, suggesting a premium valuation. However, this premium is justified by its 98.3% gross margin (vs. industry ~60%) and the potential for accelerated growth from Lifyorli. The forward P/E of 28.2x implies expected earnings growth of ~30%, which is achievable if the new drug ramps. Historically, the stock's P/E has ranged from 17.7x to 150.3x, and the current level is below the 5-year average of ~40x, indicating it may be fairly valued relative to its own history.
Corcept is a good buy for investors with a moderate risk tolerance who believe in the commercial potential of Lifyorli. The stock offers 7.7% upside to the average analyst target of $97.50 and trades at a trailing P/E of 36.6x, below its 5-year average. However, the Q1 net loss and decelerating revenue growth introduce risk. The biggest downside is a 20% decline to the analyst low target of $72 if Lifyorli disappoints. For long-term investors, the strong balance sheet and pipeline provide a favorable risk/reward, but short-term traders should be cautious given the recent 96% surge.
Corcept is better suited for long-term investment due to its low beta of 0.46, strong balance sheet, and pipeline potential. The stock has low volatility compared to peers, making it less attractive for short-term trading. A minimum holding period of 12-24 months is recommended to allow Lifyorli to contribute meaningfully to revenue and for pipeline catalysts to materialize. Short-term traders may find the recent momentum appealing, but the elevated short ratio and recent pullback from highs suggest caution.